Impact BioMedical, INC. (IBO) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$418.00K*; Operating income -$702.00K; Depreciation and amortization $284.00K*.
- 2026-03-31: Basis Reported; EBITDA -$2M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$884,000.00; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$660.00K*; Operating income -$948.00K; Depreciation and amortization $288.00K*.
Complete source-backed ebitda history.
- Available history
- 2022-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$418.00K* | -$702.00K | $284.00K* | $3.00K | -13933.33%* | (m) | $470.00K* | (m) | $76.00K | $167.00K | (m) |
|---|
| 2026-03-31 | Reported | -$2M | (m) | (m) | (m) | -28628.57% | (m) | -$464.00K | (m) | $46.00K | $1.62M | (m) |
|---|
| 2025-12-31 | Reported | -$884,000.00 | (m) | (m) | (m) | -12628.57% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$660.00K* | -$948.00K | $288.00K* | $18.00K | -3666.67%* | (m) | -$613.00K* | $1.00K | $52.00K | $261.00K | (m) |
|---|
| 2025-06-30 | Reported | -$865.00K* | -$1.15M | $288.00K* | $7.00K | -12357.14%* | (m) | -$694.00K* | $11.00K | $75.00K | $246.00K | (m) |
|---|
| 2025-03-31 | Reported | -$727,000.00 | (m) | (m) | (m) | (m) | (m) | -$682.00K | (m) | $103.00K | $248.00K | (m) |
|---|
| 2024-12-31 | Reported | -$25.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$846.00K* | -$1.13M | $281.00K* | (m) | (m) | (m) | -$1.00M* | (m) | $82.00K | $132.00K | (m) |
|---|
| 2024-06-30 | Reported | -$347.00K* | -$626.00K | $279.00K* | (m) | (m) | (m) | -$385.00K* | (m) | $121.00K | $145.00K | (m) |
|---|
| 2024-03-31 | Reported | -$491,000.00 | (m) | (m) | (m) | (m) | (m) | -$482.00K | (m) | $183.00K | $148.00K | (m) |
|---|
| 2023-12-31 | Reported | -$859,000.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$798.00K* | -$1.08M | $280.00K* | (m) | (m) | (m) | -$671.00K* | (m) | $357.00K | $101.00K | (m) |
|---|
| 2023-06-30 | Reported | -$728.00K* | -$1.01M | $280.00K* | (m) | (m) | (m) | -$733.00K* | (m) | $266.00K | $41.00K | (m) |
|---|
| 2023-03-31 | Reported | -$523,000.00 | (m) | (m) | (m) | (m) | (m) | -$1.01M | (m) | $179.00K | $40.00K | (m) |
|---|
| 2022-12-31 | Reported | -$754,000.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$610.00K* | -$889.00K | $279.00K* | $0.00* | (m) | (m) | -$802.00K* | (m) | $330.00K | $90.00K | $1.26M |
|---|
| 2022-06-30 | Reported | (m) | -$750.00K | (m) | $50.00K | (m) | (m) | (m) | (m) | $206.00K | $58.00K | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$3.14M | (m) | (m) | (m) | -9803.13% | (m) | -$1.89M | $424.00K | $340.00K | $873.00K | -$2.58M |
|---|
| 2024-12-31 | Reported | -$27.63M | (m) | (m) | (m) | (m) | (m) | -$2.85M | (m) | $278.00K | $718.00K | $33.00K |
|---|
| 2023-12-31 | Reported | -$2.91M | (m) | (m) | (m) | (m) | (m) | -$2.85M | (m) | $1.69M | $315.00K | (m) |
|---|
| 2022-12-31 | Reported | -$2.29M | (m) | (m) | (m) | -4582.00% | (m) | -$2.24M | (m) | $1.23M | $325.00K | -$621.00K |
|---|